Selected anti-CD20 mAbs in clinical development
| Antibody . | Antibody type . | Format . | Sponsor . | Stage of development . |
|---|---|---|---|---|
| Ocrelizumab (PRO70769)45 | I | Humanized IgG1 (2H7) with increased binding to FcγRIIIa and decreased CDC | Genentech/Roche/Biogen | Phase 3 trials for NHL and autoimmune conditions |
| Ofatuzumab (HuMax CD20) | I | Human (Ig transgenic mice) IgG1 with high CDC | Genmab AC/GSK | Phase 3 trials for NHL and autoimmune conditions |
| TRU-015 | I | SMIP with high affinity for CD20, strong ADCC activity, and weak CDC | Trubion Pharrma/Wyeth | Phase 1/2 in in RA |
| Veltuzumab (Ah20) | I | Humanized (similar binding and activity to rituximab) | Immunomedics | Phase 1/2 in NHL and ITP (including delivery by subcutaneous route) |
| AME-133v46 | I | Humanized IgG1 selected for increased binding to CD20 and FcRIIIa leading to augmented ADCC | Applied Molecular Evolution/Eli Lilly | Phase 1/2 in relapsed NHL |
| PRO131921 (version 114) | I | Humanized IgG1 version of LyB-1 with elbow mutations and modified Fc glycosylation giving augmented ADCC and PCD | Genentech | Phase 1/2 in CLL and NHL |
| GA101 | II | Third-generation anti-CD20 engineered from LyB-1 with optimized Fc activity (ADCC) | Glycart/Roche | Phase 1 initiated |
| Antibody . | Antibody type . | Format . | Sponsor . | Stage of development . |
|---|---|---|---|---|
| Ocrelizumab (PRO70769)45 | I | Humanized IgG1 (2H7) with increased binding to FcγRIIIa and decreased CDC | Genentech/Roche/Biogen | Phase 3 trials for NHL and autoimmune conditions |
| Ofatuzumab (HuMax CD20) | I | Human (Ig transgenic mice) IgG1 with high CDC | Genmab AC/GSK | Phase 3 trials for NHL and autoimmune conditions |
| TRU-015 | I | SMIP with high affinity for CD20, strong ADCC activity, and weak CDC | Trubion Pharrma/Wyeth | Phase 1/2 in in RA |
| Veltuzumab (Ah20) | I | Humanized (similar binding and activity to rituximab) | Immunomedics | Phase 1/2 in NHL and ITP (including delivery by subcutaneous route) |
| AME-133v46 | I | Humanized IgG1 selected for increased binding to CD20 and FcRIIIa leading to augmented ADCC | Applied Molecular Evolution/Eli Lilly | Phase 1/2 in relapsed NHL |
| PRO131921 (version 114) | I | Humanized IgG1 version of LyB-1 with elbow mutations and modified Fc glycosylation giving augmented ADCC and PCD | Genentech | Phase 1/2 in CLL and NHL |
| GA101 | II | Third-generation anti-CD20 engineered from LyB-1 with optimized Fc activity (ADCC) | Glycart/Roche | Phase 1 initiated |
Data modified from Maloney.44
SMIP indicates small modular immunopharmaceutical drug composed of human IgG1 Fc and hinge regions (hinge, CH2, and CH3) linked directly to an anti-CD20 scFv.